1. Generics Bulletin
  2. >>Products

Benepali Surge And Imraldi Gains Drive Biogen Biosimilars Past US$500m

 
• By Dean Rudge

With sales climbing by more than two-fifths last year, Biogen expects its biosimilar sales to continue to grow by double digits in 2019, driven by the launch of the Imraldi adalimumab biosimilar in mid-October last year.

Car
The US$500m biosimilar sales barrier has been smashed by Biogen, with double-digit growth forecast in 2019 • Source: Shutterstock

Becoming the first company to offer the three main anti-TNF biosimilars across Europe, combined with enjoying its most successful launch of a biosimilar, allowed Biogen to report biosimilar sales that crashed through the US$500 million barrier in 2018.

Sales boomed by 44% to US$545 million, driven by the launch of Imraldi (adalimumab) in mid-October “in several European markets,” as well as strong gains for Benepali (etanercept) and Flixabi (infliximab); the two other biosimilars Biogen sells in Europe

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products